this whole deal with Cyrus is so bizaar that i don
Post# of 148278
It does seem the difficulty in working with the FDA and the BOD might have been more difficult than what Cyrus planned. It is obvious the Board really does not want any communication than necessary in a complete 180 from how Nader ran things. I miss the near term goal that Nader was able to put in front of us, wasn't it nice anticipating the trial results from so many indications?
I don't think there is a buy out in the works because Cyrus would have to be really stupid to not hold out until the deal is done if there was one. could be the BOD told Cyrus to find another job and let him be part time until he did? on the other hand, This BOD is built for deals, not clinical trials. They are good at partnership agreements and buy outs. raising funds and conduction trials is not on the resumes from those in charge. they made it clear that no trials or studies will happen without a partner. could be the hold is the hurdle to get to the partnerships, but the BOD sure is keeping it a secret.
the other really interesting development is who the next CEO will be, could be someone who looks at the HIV BLA as worth salvaging. maybe the FDA's questions make finishing off the BLA not as much of a hill to climb?
I do agree, the annual meeting will likely be administrative as this is a required meeting and these rarely correspond to actual PR type announcements. the hold being lifted has nothing to do with the annual meeting. If we don't get a good update on the status of everything, i Think everyone at cytodyn will get a inbox full of irritated emails from us, that is for sure.